Výsledky vyhledávání - "S B Connelly"

P334 Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme

Autor: Julià Panés, S B Connelly, Rajiv Mundayat, Nancy Sunna, Gerhard Rogler, Nervin Lawendy, Ala I. Sharara, Ryan C. Ungaro, Matthew A. Ciorba

Publikováno v: Journal of Crohn's and Colitis. 15:S357-S359

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). We present an updated analysis of adjudicated malignancies in the tofacitinib UC clinical programme, including final data from the open-labe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2dce3e37bf8d26ea56fc4016d067d0a8
https://doi.org/10.1093/ecco-jcc/jjab076.458

Zobrazit plný text záznamu

DOP59 Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore

Autor: Nervin Lawendy, Krisztina Gecse, Flavio Steinwurz, S B Connelly, Jessica R. Allegretti, Jerome Paulissen, Scott D. Lee

Publikováno v: Journal of Crohn's and Colitis. 15:S094-S095

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib in patients (pts) with UC were evaluated in two 8-week, Phase 3 induction studies (OCTAVE Induction 1&2),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b870c30cf1a4fbf6cc1fc84313f5f868
https://doi.org/10.1093/ecco-jcc/jjab073.098

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání